AKAP17A: A Potential Drug Target and Biomarker for ALS (G8227)

Target Name: AKAP17A

NCBI ID: G8227

AKAP17A

AKAP17A: A Potential Drug Target and Biomarker for ALS

Acidic carabosamine (Alzheimer's disease-associated protein 17A, AKAP17A) is a protein that is normally found in brain tissue but is abnormally increased in Alzheimer's disease patients. It is one of the main causative factors of Alzheimer's disease (ALS) and is closely related to reduced patient survival and disease progression. In recent years, researchers have conducted in-depth studies on the structure, function and potential drug targets of AKAP17A, and discovered its important position in drug research and development. This article will review the biological functions, clinical applications and drug targets of AKAP17A.

1. Biological functions

AKAP17A is an acidic protein with a molecular weight of 28.5 kDa. It is normally located in brain tissue, including the brain, spinal cord, and peripheral nervous tissue. In patients with Alzheimer's disease, abnormal increases in AKAP17A may lead to neuronal damage and nerve cell death, thereby exacerbating disease progression.

2. Clinical application

Currently, AKAP17A has become a research hotspot in the field of Alzheimer's disease. By conducting genetic sequencing and proteomic analysis on patients, the researchers found that many genes and proteins related to AKAP17A played an important role in disease progression. In addition, the expression level of AKAP17A is closely related to patient survival rate and quality of life.

3. Drug Targets

AKAP17A is considered a potential target in drug development because many studies have demonstrated that inhibiting the activity of AKAP17A can prolong the manifestation time and improve survival rates of Alzheimer's disease patients. Currently, a variety of drugs have entered clinical research, aiming to inhibit the activity of AKAP17A, including anti-neuronal apoptosis drugs, anti-inflammatory drugs and immunomodulators.

4. Biological mechanism of AKAP17A

Abnormal increases in AKAP17A are closely related to neuronal damage and nerve cell death in Alzheimer's disease. Studies have shown that overexpression of AKAP17A may lead to neuronal apoptosis, and apoptosis is one of the main mechanisms of neuronal damage and nerve cell death. In addition, AKAP17A is also related to neuronal oxidative stress and neuronal damage repair.

5. Summary

AKAP17A is a protein that is abnormally increased in Alzheimer's disease patients. It has biological functions and is closely related to disease progression and patient survival. In recent years, AKAP17A has become a hot topic in the field of drug research and development, and a variety of drugs have entered clinical research aimed at inhibiting the activity of AKAP17A. With the deepening of research, AKAP17A is expected to become an important target for the treatment of Alzheimer's disease.

Protein Name: A-kinase Anchoring Protein 17A

Functions: Splice factor regulating alternative splice site selection for certain mRNA precursors. Mediates regulation of pre-mRNA splicing in a PKA-dependent manner

The "AKAP17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKAP17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets